Top Back to top

RATG: Prospective Phase II Pilot study of Rabbit Antithymocyte globulin (ATG, Thymoglobuline®, Genzyme) with Ciclosporin for Patients with Acquired Aplastic Anaemia and comparison with matched historical patients treated with horse ATG and Ciclosporin

Study number:
2007-00902-55
Type of transplant:
 
Short title:
RATGAA07
Study status:
Completed Patient Recruitment
Deadline for data collection:
 
Study design:
Non-randomized,prospective,multi-centre, phaseII pilot study
Primary objective:
Assess tolerability and efficacy of rabbit ATG (Thymoglobuline®) with CSA in the first line treatment of patients with acquired SAA, and patients with NSAA
Key inclusion criteria:
>=16years (18 in DE + CH)
Country:
France
Germany
Italy
Saudi Arabia
Switzerland
United Kingdom
Principal investigator:
Judith Marsh
Principal investigator email:
 
EBMT Study coordinator:
Alain Barrois

Need help?

The personal data provided will be processed according to the General Data Protection Regulation (GDPR 2016/679 ) and incorporated to a file property of EBMT which will be allocated in the EEA (European Economic Area) or in countries that are provided with the same level of protection for privacy such as countries that adhere to EU-US and Swiss-US Privacy Shield Frameworks.
Data Subjects have the right of access to his or her data and the right to rectification of any inaccurate or incomplete personal data. The Data Subject also has the right to withdraw consent, this wish will be respected, and the personal will no longer be made available. If the processing operation is unlawful the Data Subject has the right to request deletion of that data. Please write to data.protection@ebmt.org